Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals PLC announced that its Annual General Meeting (AGM), originally scheduled for June 17, 2026, was adjourned due to a lack of quorum. The company has re-scheduled the AGM to take place on June 30, 2026, at 11:00 a.m. London time, at its registered office in Cardiff. Proxies submitted for the initial meeting will remain valid for the re-scheduled AGM.

Biodexa Pharmaceuticals Plc announced its Annual General Meeting (AGM) will be held on June 17, 2026, to consider several resolutions, including a significant reorganization of its share capital. The proposed changes aim to rationalize the company's share capital by reducing the number of ordinary shares outstanding without affecting shareholders' rights or proportionate ownership. This involves a reverse split, subdivision of shares, and an adjustment to the ordinary share to American Depositary Share (ADS) ratio, which the Board unanimously recommends shareholders approve.

Biodexa Pharmaceuticals Plc has issued a letter to shareholders detailing proposals for a share capital reorganization at its upcoming Annual General Meeting on June 17, 2026. The plan aims to rationalize the company's exceptionally large number of ordinary shares by implementing a reverse split, subdivision, and creating E deferred shares, without affecting shareholder rights, proportionate ownership, or the number of ADSs outstanding. The Board unanimously recommends shareholders vote in favor of these resolutions, which will be effective June 18, 2026, if passed.